期刊文献+

Plackett-Burman与响应面法相结合优化化学成分明确的MDCK细胞无血清无蛋白培养基 被引量:4

Optimization of chemically defined serum- and protein-free medium for MDCK cells by Plackett-Burman experiment design combined with response surface analysis
原文传递
导出
摘要 目的采用Plackett-Burman与响应面法相结合优化化学成分明确的MDCK细胞无血清无蛋白培养基。方法在自主研发的含蛋白无血清培养基的基础上,通过Plackett-Burman试验和响应面试验设计考察23组营养物质对MDCK细胞生长的影响,以细胞比生长速率、维持时间及最大活细胞密度作为响应值进行筛选和定量优化。以最优化的因子浓度配制化学成分明确的无血清无蛋白培养基,分别于细胞培养板和搅拌瓶中培养MDCK细胞,考察细胞比生长速率、维持时间和最大活细胞密度3个响应值的大小。结果通过Plackett-Burman试验筛选出4种对MDCK细胞生长具有显著性促进作用的因子:半胱氨酸、苏氨酸、亮氨酸和葡萄糖,苏氨酸和亮氨酸有助于提高细胞比生长速率,半胱氨酸和葡萄糖有利于提高最大活细胞密度;该化学成分明确的无血清无蛋白培养基能很好地支持MDCK细胞悬浮生长,单细胞悬浮培养MDCK细胞时,细胞比生长速率可达0.058/h,最大活细胞密度可达32.65×105个/ml,分别比基础培养基提高了2.15和3.09倍。结论采用Plackett-Burman与响应面法相结合优化了化学成分明确的MDCK细胞无血清无蛋白培养基,为采用MDCK细胞大规模工业化生产流感疫苗奠定了基础。 Objective To optimize chemically defined serum- and protein-free medium for MDCK cells by Plackett-Burman experiment design combined with response surface analysis. Methods For component screening and quantitative optimization, 23 groups of nutrients were investigated by the Plackett-Burman design and response surface analysis based on an in-house protein containing serum-free medium serving the specific growth rate, time duration and maximum viable cell density as response values. Chemical defined serum- and protein-free medium was formulated with the components at optimal concentrations, with which MDCK cells were cultured in cell culture plate and stirring bottle, and the response values were evaluated. Results Four factors promoting the growth of MDCK cells significantly, cysteine, threonine, leucine and glucose, were screened by Plackett-Burman test. Threonine and lecucine were helpful to increasing the specific cell growth rate, while cysteine and glucose to increasing maximum viable cell density. The chemical defined serum-free and protein-free medium supported the suspending growth of MDCK cells effectively. The specific growth rate and maximum viable cell density of MDCK cells in single-cell suspension culture reached 0. 058/h and 32. 65 × 10^5 cells/ml, which are 2. 15 and 3. 09 times higher than those in basal medium, respectively. Conclusion The chemically definedserum- and protein-free medium for MDCK cells was optimized by Plackett-Burman experiment design combined with response surface analysis, which laid a foundation of industrial production of influenza vaccine by using MDCK cells.
出处 《中国生物制品学杂志》 CAS CSCD 2014年第6期835-842,共8页 Chinese Journal of Biologicals
基金 国家自然科学基金资助项目(21206040) 国家科技重大专项基金资助项目(2013ZX10004003-003-003)
关键词 MDCK细胞 无蛋白培养基 Plackett-Burman试验设计 响应面分析 MDCK cells Protein-free medium Plackett-Burman experiment design Response surface analysis
  • 相关文献

参考文献15

  • 1刘旭平,范里,朱明龙,张旭,谭文松.MOI对HEK293细胞感染病毒后的生长代谢和腺病毒扩增效率的影响[J].高校化学工程学报,2010,24(4):638-644. 被引量:7
  • 2刘国庆,陈飞,赵亮,范里,谭文松.表达单克隆抗体的CHO细胞无蛋白培养基的优化[J].高校化学工程学报,2013,27(1):96-101. 被引量:10
  • 3Schroder M,Matischak K,Friedl P.Serum-and protein-free media formulations for the Chinese hamster ovary cell line DUKXB11[J].J Biotechnol,2004,108(3):279-292.
  • 4Sung YH,Lim SW,Chung JY,et al.Yeast hydrolysate as a low-cost additive to serum-free medium for the production of human thrombopoietin in suspension cultures of Chinese hamster ovary cells[J].Appl Microbiol Biotechnol,2004,63(5):527-536.
  • 5Stoll TS,Muhlethaler K,von Stockar U,et al.Systematic improvement of a chemically-defined protein-free medium for hybridoma growth and monoc lonal antibody production[J].J Biotechnol,1996,45(2):111-123.
  • 6Wood JM,Levandowski RA.The influenza vaccine licensing process[J].Vaccine,2003,21(16):1786-1788.
  • 7Genzel Y,Reichl U.Continuous cell lines as a production system for influenza vaccines[J].Expert Rev Vaccines,2009,8(12):1681-1692.
  • 8Gredersen JP,Schmitt HJ,Trusheim H,et al.Safety of MDCK cell culture-based influenza vaccines[J].Future Microbiol,2011,6(2):143-152.
  • 9Onions D,Egan W,Jarrett R,et al.Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine[J].Biologicals,2010,38(5):544-551.
  • 10Genzel Y,Dietzsch C,Rapp E,et al.MDCK and Vero cells for influenza virus vaccine production:a one-to-one comparison up to lab-scale bioreactor cultivation[J].Appl Microbiol Biotechnol,2010,88(2):461-475.

二级参考文献26

  • 1陈英文,黄任远,沈树宝,高坤,胡云龙.用高效廉价载体培养CHO细胞生产rHuEPO的研究[J].高校化学工程学报,2005,19(6):855-858. 被引量:1
  • 2高量,游磊,朱明龙,谭文松.rCHO细胞在葡萄糖限制流加培养过程中的生长与代谢特性[J].高校化学工程学报,2006,20(1):74-78. 被引量:14
  • 3Kamen A,Henry O.Development and optimization of an adenovirus production process[J].J Gen Med,2004,6(1):184-192.
  • 4Jardon M,Garnier A.pH,pCO2,and temperature effect on R-adenovirus production[J].Biotechnol Prog,2003,19(1):202-208.
  • 5Ferreira T B,Ferreira A L,Carrondo M J T et al.Effect of reefed strategies and non-ammoniagenic medium on adenovirus production at high cell densities[J].J Biotechnol,2005,119(3):272-280.
  • 6Kim M,Zinn K R,Barnett B G et al.The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells[J].Eur J Cancer,2002,38(14):1917-1926.
  • 7Seidman M A,Hogan S M,Wendland R L et al.Variation in adenovirus receptor expression and adenovirus vector-mediated transgene expression at defined stages of the cell cycle[J].Mol Ther,2001,4(1):13-21.
  • 8Garnier A,Cote J,Nadeau I et al.Scale-up of the adenovirus expression system for the production of recombinant protein in human 293S cells[J].Cytotechnology,1994,15(1-3):145-155.
  • 9Nadeau I,Kamen A.Production of adenovirus vector for gene therapy[J].Biotechnol Adv,2003,20(7-8):475-489.
  • 10Nadeau I,Garnier A,Cote J et al.Improvement of recombinant protein production with human adenovirus/293S expression system using fed-batch strategies[J].Biotechnol Bioeng,1996,51(6):613-623.

共引文献15

同被引文献36

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部